HighGravityDataBioMarin Pharmaceutical — Feb 19, 2025 release
Fiscal 2024 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001048477-25-000004
Showing in the filing
Revenue and profitability growth
“Double-Digit”
Period
FY2025
Measure
GAAP-tied
Source
Prose
All guidance in this release · 14
Revenue and profitability growth for FY2025
“Double-Digit”
VOXZOGO country availability for FY2027
“more than 60 countries”
VOXZOGO Revenue CAGR for FY2023
“exceeding 25%”
Enzyme Therapies long-term growth outlook (C… for the long term
“high single-digit CAGR”
Cost transformation program size for FY2024
“$500 million”
Non-GAAP Operating Margin for FY2026
“40%”
Total Revenues for FY2027
“approximately $4 billion”
Non-GAAP Operating Margin growth for FY2025
“14% (3.9 percentage points) Y/Y at the mid-point of guidance”
Operating cash flows for FY2027
“more than $1.25 billion”
Total Revenues for FY2025
“$3,100 to $3,200”
Non-GAAP Operating Margin % for FY2025
“32% to 33%”
Non-GAAP Diluted EPS for FY2025
“$4.20 to $4.40”
VOXZOGO contribution to full-year 2025 Total… for FY2025
“$900 million to $950 million”
Weighted-Average Diluted Shares Outstanding … for FY2025
“approximately 200 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
(415) 455-7558 (650) 374-2803 BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance Strong Execution and Operational Transformation in 2024 Delivered Record Full Year Results and Provides Momentum for Double-Digit Revenue and Profitability Growth in 2025 4Q 2024 Total Revenues of $747 million (+16% Y/Y and +21% at Constant Currency Y/Y); FY 2024 Total Revenues of $2.85 billion (+18% Y/Y and +22% at Constant Currency Y/Y) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif., February 19, 2025 – BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2024. “Our operational transformation and strong financial execution in 2024 is the first step in BioMarin’s ambitious multiyear growth plan,” said Alexander Hardy, President and Chief Executive Officer of BioMarin. “We begin 2025 ready to build on our leadership in treating genetically defined conditions and deliver breakthrough medicines to the patients we serve. This year, we expect a number of innovative pipeline candidates to advance, including BMN 351 for Duchenne Muscular Dystrophy, and BMN 333 for multiple skeletal conditions, that will yield early clinical data read-outs, as well as results from the Phase 3 PALYNZIQ ® study for the treatment of adolescents with phenylketonuria between the ages of 12 and 17. We plan to submit applicatio
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.